You are here
VIROGENOMICS, INC.
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Development of Neuroprotective Stroke Thereapy
Amount: $123,759.00DESCRIPTION (provided by applicant): The potential of treatment for stroke may be accomplished via acute intervention at the time of the acute stroke or by providing prophylactic neuroprotection to a ...
STTRPhase I2008Department of Health and Human Services National Institutes of Health -
Immunotherapeutic Approaches to Cancer Treatment
Amount: $123,614.00DESCRIPTION (provided by applicant): Immunotherapy as a treatment for cancer has been intensely investigated, but few studies have resulted in meaningful clinical responses. Many fundamental principal ...
STTRPhase I2008Department of Health and Human Services National Institutes of Health -
Genetically Defined Attenuated Living Vaccine for Francisella
Amount: $289,487.00DESCRIPTION (provided by applicant): Tularemia is the severe and sometimes fatal disease caused by infection with Francisella tularensis. These bacteria are some of the most virulent pathogens known, ...
STTRPhase I2007Department of Health and Human Services National Institutes of Health -
HLA-DQ-derived RTLs for Treatment of Celiac Disease
Amount: $751,424.00DESCRIPTION (provided by applicant): Celiac disease is an inflammatory autoimmune disease in which CD4+ T cells target, damage and eventually destroy the villous tissue structures of the small intesti ...
STTRPhase II2006Department of Health and Human Services National Institutes of Health -
Recombinant T-cell Receptor Ligands for Treatment of Uveitis
Amount: $100,726.00DESCRIPTION (provided by applicant): Uveitis is a group of inflammatory eye diseases, often associated with an underlying autoimmune disease process. It is currently estimated that each year in the Un ...
STTRPhase I2006Department of Health and Human Services National Institutes of Health -
HLA-DQ-derived RTLs for Treatment of Celiac Disease
Amount: $751,424.00DESCRIPTION (provided by applicant): Celiac disease is an inflammatory autoimmune disease in which CD4+ T cells target, damage and eventually destroy the villous tissue structures of the small intesti ...
SBIRPhase II2006Department of Health and Human Services National Institutes of Health -
Recombinant T-cell Receptor Ligands for Treatment of Uveitis
Amount: $100,726.00DESCRIPTION (provided by applicant): Uveitis is a group of inflammatory eye diseases, often associated with an underlying autoimmune disease process. It is currently estimated that each year in the Un ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health -
Osteopontin, a Novel Neuroprotectant in Brain Ischemia
Amount: $751,716.00DESCRIPTION (provided by applicant): This is an STTR Phase II proposal to develop the application of a novel neuroprotectant in the treatment of stroke. As in our previous Phase I STTR, this Phase II ...
STTRPhase II2005Department of Health and Human Services National Institutes of Health -
HLA-DR4-derived RTLs for Treating Rheumatoid Arthritis
Amount: $100,548.00DESCRIPTION (provided by applicant): The specific goal of this Phase I STTR is to design, manufacture, characterize and evaluate a set of therapeutic agents that can control the pathogenic CD4+ T cell ...
STTRPhase I2005Department of Health and Human Services National Institutes of Health -
Osteopontin, a Novel Neuroprotectant in Brain Ischemia
Amount: $751,716.00DESCRIPTION (provided by applicant): This is an STTR Phase II proposal to develop the application of a novel neuroprotectant in the treatment of stroke. As in our previous Phase I STTR, this Phase II ...
SBIRPhase II2005Department of Health and Human Services National Institutes of Health